Submit an Article
Navigate
Home
Editorial Board
Editorial Policies
Current Volume
Archive
Scientific Integrity
Publication Ethics Statements
Interviews with Outstanding Authors
Newsroom
Sponsored Conferences
Podcast
Contact
Special Collections
Submit an Article
Online ISSN: 1945-4589
Research Paper
|
Volume 8, Issue 12
|
pp. 3520–3534
Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer
Back to article
Figure 5D
(8 of 11)
−
100%
+
Figure 5D.
Immunohistochemical analysis for MVD in HepG2 xenografts and combination therapy enhanced the inhibition of tumor angiogenesis in vivo. Magnification, 200×. *p < 0.05, vs MSC.sFlt1 plus continuous low-dose doxorubicin group.
